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Aspergillus is the causative agent of human diseases ranging from asthma to invasive
infection. Genetic and environmental factors are crucial in regulating the interaction
between the host and Aspergillus. The role played by the enzyme indoleamine
2,3-dioxygenase 1 (IDO1), which catalyzes the first and rate-limiting step of tryptophan
catabolism along the kynurenine pathway, is increasingly being recognized, but whether
and how genetic variation of IDO1 influences the risk of aspergillosis in susceptible
patients is incompletely understood. In addition, whether the closely related protein IDO2
plays a similar role remains unexplored. In the present study, we performed genetic
association studies in two different cohorts of susceptible patients [cystic fibrosis (CF)
patients and recipients of hematopoietic stem cell transplantation (HSCT)], and identified
IDO1 polymorphisms that associate with the risk of infection in both cohorts. By using
human bronchial epithelial cells and PBMC from CF and HSCT patients, respectively, we
could show that the IDO1 polymorphisms appeared to down-modulate IDO1 expression
and function in response to IFNγ or Aspergillus conidia, and to associate with an
increased inflammatory response. In contrast, IDO2 polymorphisms, including variants
known to profoundly affect protein expression and function, were differently associated
with the risk of aspergillosis in the two cohorts of patients as no association was found
in CF patients as opposed to recipients of HSCT. By resorting to a murine model of bone
marrow transplantation, we could show that the absence of IDO2 more severely affected
fungal burden and lung pathology upon infection with Aspergillus as compared to IDO1,
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and this effect appeared to be linked to a deficit in the antifungal effector phagocytic
activity. Thus, our study confirms and extends the role of IDO1 in the response to
Aspergillus, and shed light on the possible involvement of IDO2 in specific clinical settings.
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INTRODUCTION
Aspergillus species are environmental fungi to which humans
are constantly exposed and the inability to properly control
the invasion results in a wide spectrum of diseases, ranging
from asthma to the more severe and life-threatening invasive
aspergillosis (IA) (1). The host immune response as well as the
degree of exposure are critical determinants for the development
of infection and gauge the clinical manifestations of aspergillosis.
Indeed, specific diseases and/or clinical conditions unbalance the
immune response to Aspergillus and favor the development of
characteristic fungal infections. One such example is represented
by cystic fibrosis (CF, OMIM#219700), an autosomal recessive
disorder caused by mutations in the gene encoding for the
Cystic Fibrosis transmembrane conductance regulator (CFTR,
on chr. 7q31.2), a chloride/bicarbonate channel that regulates
the electrolyte content of luminal fluid. CFTR mutations result
in viscid secretion and defective airway mucociliary clearance
providing a suitable environment for persistent microbial
colonization (2). CF patients typically develop an extreme form of
asthma, named allergic bronchopulmonary aspergillosis (ABPA),
characterized by an exaggerated hypersensitivity reaction and
associated with progressive lung function decline. More severe
manifestations of Aspergillus-related diseases, such as IA, are
rare in CF patients (3). In contrast, severe IA occur in severely
immunocompromised patients such as those diagnosed with
acute leukemia and chronic lymphoproliferative disorders, or
recipients of allogeneic hematopoietic stem cell and solid-organ
transplants (4).
The host immune response to Aspergillus has been extensively
investigated and different cell types and signaling pathways have
been brought into play (5). A central role at the Aspergillus/host
interface is thought to be played by the enzyme indoleamine 2,3-
dioxygenase 1 (IDO1) that, along with IDO2 and tryptophan
2,3-dioxygenase (TDO), catalyzes the first and rate-limiting
step of tryptophan catabolism along the kynurenine pathway
(6). IDO1 is expressed by several immune and non-immune
cells and is recognized as a suppressor of inflammation and
regulator of immune homeostasis, and failure to balance
IDO1-mediated tolerance with the inflammatory response has
been implicated in a wide range of diseases (7). Indeed, our
group has recently shown that IDO1 enzyme was defective
in murine CF and the decreased tryptophan/kynurenine
metabolism was causally linked to Aspergillus infection via an
unbalanced type 17 helper T cell/regulatory T cell response
(8). Similarly, IDO1 has gained attention for its ability
to control inflammation, pathogen immunity and tolerance
in transplant recipients eventually leading to prevention of
graft-vs-host reaction and reduction of aspergillosis incidence
rates (9).
An additional level of complexity in the relationship
between Aspergillus and the host is represented by the
individual genetic background. Indeed, the presence of single-
nucleotide polymorphisms (SNPs) that alter the expression
and/or function of the molecules engaged in the cross-talk with
Aspergillus may skew the balance between inflammation and
tolerance and impact on the individual response to infection
(9). Polymorphisms in the genes encoding for the enzymes
involved in the kynurenine pathway, including IDO1, have
been associated with several diseases (10). In the setting of
fungal infection, our group has shown that IDO1 rs3808606 T/T
genotype correlated with a decreased susceptibility to recurrent
vulvovaginal candidiasis and was associated with high levels
of IL-22 and decreased levels of IL-17A and TNFα, enhanced
IDO1 expression in vaginal cells and increased kynurenine-to-
tryptophan ratio (11).
IDO biology has been recently enriched by the identification
of a closely related protein, named IDO2 (12–14). IDO1 and
IDO2 genes are adjacent to each other on chromosome 8p11.21
and likely arose by gene duplication before the divergence of
vertebrates (15). In spite of the structural homology and the
similar enzymatic activity, although with lower affinity, the
function of IDO2 is still disputed, as well as how it coordinates
with IDO1 activity (16).
Based on these premises, we have analyzed IDO1/IDO2
polymorphisms in two different cohorts of patients, i.e., CF
patients and recipients of hematopoietic stem cell transplantation
(HSCT). We found that polymorphisms affecting the expression
and/or function of IDO1 associate with increased risk of
aspergillosis in the two cohorts of patients. In contrast, IDO2
appears to be dispensable in CF but required for optimal
antifungal effector phagocytic activity in HSCT.
MATERIALS AND METHODS
Ethics Statement
Murine experiments were carried out according to Italian
Approved Animal Welfare Authorization 360/2015-PR and
Legislative Decree 26/2014 regarding the animal license obtained
by the Italian Ministry of Health lasting for 5 years (2015–2020).
The human study approval was provided by the University
of Perugia ethics committee (Prot. 2012-043) and institutional
review boards at each site. Written informed consent was
obtained from all the participants, or, in case of minors, from
parents or guardian.
Cohort of CF Patients
Two hundred seventy-two Caucasian patients who had a proven
diagnosis of CF (CFTR genotyping, sweat testing, and clinical
phenotype) were enrolled in the study. Clinical records from each
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TABLE 1 | Demographic and clinical characteristics of CF patients.
N Mean ± S.D. Range
Age in years: 272 15.5 ± 11.4 0.1 - 56
Age at diagnosis in months: 255 31.8 ± 70.6 0 - 408
FEV1, % predicted: 204 84.8 ± 26.7 22 - 134
FVC, % predicted: 204 91.1 ± 21.7 29 - 131
Height, cm: 213 151.1 ± 24.6 71 - 192
Weight, kg: 213 48.7 ± 19.0 8 - 103
BMI: 211 20.2 ± 3.8 13 - 42
N Percent
Sex: Male 131 48.2%
Female 141 51.8%
CFTR mutation: 1F508
homozygous
72 26.8%
1F508
heterozygous
125 46.4%
Other 72 26.8%
Microbiological status Status N Percent
Aspergillus Yes 76 27.9%
No 196 72.1%
FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; BMI, body
mass index; CFTR, cystic fibrosis transmembrane conductance regulator. Continuous
variables are expressed as mean ± SD.
patient were reviewed and clinical data including age, gender,
lung function testing, measures of nutrition, microbiological
findings, and vital status were recorded (Table 1). A. fumigatus
positivity was defined as the presence of persistent positive
Aspergillus cultures, but negative galactomannan and no
immunological responses or bacterial positivity as persistent, for
at least 6 months. Study approval was obtained from institutional
review boards at each site and written informed consent was
obtained from the participants, or, in case of minors, from
parents or guardian.
Cohort of Hematological Patients
Undergone HSCT
Three hundred fifty-two adult patients with hematologic
disorders undergoing allogeneic HSCT at the transplantation
center in Perugia (Italy) and their respective donors were
enrolled in the study. Clinical records from each patient
were reviewed and clinical data including age, gender, disease,
transplantation type, GvHD and microbiological findings were
recorded (Table 2). Seventy-eight cases of invasive aspergillosis
were classified as “probable” or “proven,” according to the revised
standard criteria from the European Organization for Research
and Treatment of Cancer–Mycoses Study Group (17).
SNPs Selection and Genotyping
Four IDO1 SNPs (Supplementary Table 1) were selected based
on their ability to tag surrounding variants (r2 > 0.8, MAF
> 0.05) in the HapMap-CEU population of the International
HapMap project, phase III (18), using Haploview (19). Since
IDO2 gene was not annotated in the International HapMap
project, phase III, we selected four tagSNPs based on literature
review (20) and their location across IDO2 coding region
(Supplementary Table 1). Patients provided a blood specimen
for DNA isolation performed using the QIAamp DNA Mini
(Qiagen, Milan, Italy) following the manufacturer’s instructions
and stored at −20◦C. SNP genotyping was performed using
KASPar assays (LGC Genomics) according to manufacturer’s
instructions in an Applied Biosystems 7500 Fast qPCR system
(Life Technologies). Genotyping sets comprised randomly
selected replicates of previously typed samples and two negative
controls (water). Concordant genotyping was obtained for≥99%.
Hardy-Weinberg Equilibrium (HWE), Minor Allele Frequency
(MAF) and genotyping rate were determined using Haploview
(19). SNPs with a genotyping rate<90% were not included in the
genetic association testing. No HWE cut-off was applied since
both cohorts were composed by affected subjects, and in this
situation a deviation from HWE may be indicative of causative
effect at the considered loci.
Genetic Association Testing
The CF and HSCT datasets have been designed as case-control
and longitudinal study, respectively, and the analysis of their
genetic data has been performed using different approaches.
For the CF dataset, haplotype and single-SNP analyses
have been performed using PLINK (21), using logistic or
linear regression, adjusting for sex and age-at-sampling.
The association testing in the HSCT cohort was performed
by determining the cumulative incidence of IA at 24
months after transplantation applying competing risk
logistic regression models, adjusting for HLA matching and
underlying disease, considering transplant related mortality and
relapse as competing risks. Competing risk logistic regression
models were tested according to donor/recipient status using
R software (22).
Statistical significance was set up according to the different
hypotheses tested throughout the work. For the primary aim
of the study, that is testing the impact of IDO1/IDO2 loci
on Aspergillus infection in CF patients, we set up a P <
0.025 (0.05/2) for haplotype and P < 0.006 (0.05/8) for single-
SNP analysis according to Bonferroni’s correction [2 Linkage
Disequilibrium (LD) blocks for haplotype omnibus test and 8
independent SNPs]. LD blocks were defined using Haploview
(19) according to the solid spine algorithm. For the association
testing in the HSCT cohort we considered a nominal P <
0.01 (0.05/5) as statistical significance threshold given the
number of SNPs tested (N = 5). All the single-SNP analyses
have been performed according to three genetic models of
association (additive, dominant and recessive). No Bonferroni’s
correction has been applied according to the three genetic
models of association since they do not represent a mode of
independent testing.
Mice
Female, 8- to 10-weeks-old C57BL6 and Balb/c mice were
obtained from Charles River Laboratories (Calco, Italy).
B6129indo (Ido1−/−) mice were bred under specific pathogen-
free conditions in the animal facility at the University of Perugia.
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TABLE 2 | Characteristics of HSCT recipients.
Clinical variable IA
(N = 50)
Non-IA
(N = 302)
RR P
Age at transplantation–Mean ± S.D. 37.3 (13.1) 40.3 (15.0) 0.988 0.130
Females–n (%) 26 (52.0) 151 (50.0) 1.080 0.780
HLA matching, no. (%)
Transplant from haploidentical- related
donor
35 (70.0%) 146 (48.3%) 2.440 0.003
Transplant from half-matched related
donor
4 (8.0%) 79 (26.2%) 0.261 0.009
Transplant from haploidentical unrelated
donor
6 (12.0%) 51 (16.9%) 0.669 0.350
Transplant from half-matched unrelated
donor
5 (10.0%) 26 (8.6%) 1.100 0.830
Underlying disease, no. (%)
Acute leukemia (AML, ALL) 32 (64.0%) 231 (76.5%) 0.592 0.078
Lymphoma/myeloma (MM, HL, NHL-B) 13 (26.0%) 56 (18.5%) 1.440 0.248
Chronic leukemia (CML, CLL) 3 (6.0%) 14 (4.6%) 1.310 0.660
Other (SM, MDS, AA) 2 (4.0%) 1 (0.3%) 6.020 0.003
Advanced disease stage, no. (%) 29 (58.0%) 169 (56.0%) 1.100 0.720
Myeloablative conditioning regimen, no. (%)
Total-body irradiation 42 (84.0%) 229 (75.8%) 1.620 0.213
No total-body irradiation 8 (16.0%) 73 (24.1%) 0.617
CMV serology of donor and recipient, no. (%)
CMV−/CMV− 5 (10.0%) 25 (8.3%) 1.056 0.900
CMV–/CMV+, CMV+/CMV– or
CMV+/CMV+
45 (90.0%) 277 (91.7%) 0.947
GVHD, grade II to IV, no. (%) 6 (12.0%) 21 (7.0%) 1.700 0.220
P-values were calculated using competing risk logistic regression models. Statistically significant results are marked in bold. IA, invasive aspergillosis; HLA, human leukocyte antigen;
TBI, total body irradiation; CMV, cytomegalovirus; GVHD, graft-vs-host-disease.
Aspergillus fumigatus Strain and Infection
Viable conidia (95%) of A. fumigatus (Af293) were obtained
by growth on Sabouraud dextrose agar (Sigma-Aldrich)
supplemented with chloramphenicol for 5 days at room
temperature. The fungus was collected with a cell scraper after
addition of PBS, transferred in a tube, pelleted and resuspended
in PBS. After counting, the resuspension was further diluted
in PBS to reach the desidered final concentration. For in vivo
experiments, mice were anesthetized by intraperitoneal injection
of 2.5% avertin (Sigma Chemical Co, St. Louis, MO) before
intranasal instillation of a suspension of 2 × 107 resting conidia
/20 µl saline. For in vitro experiments, cells were treated at a 1:20
cell/conidia ratio.
Bone Marrow (BM) Transplantation Model
and Infection
BM cells from donor mice were prepared by differential
agglutination with soybean agglutinin. T cell-depleted cells (1 ×
107 containing 1% of contaminating T cells on FACS analysis)
were injected intravenously into recipient Balb/c mice exposed
to a lethal radiation dose of 9Gy. 95% of the mice survived,
showing a stable, donor type haematopoietic chimaerism, as
revealed by donor type major histocompatibility (MHC) class I
antigen expression on cells from spleens, as previously described
(23). BM cells from Ido2−/− mice were kindly provided by G.C.
Prendergast (Lankenau Institute for Medical Research (LIMR),
USA). Mice were monitored for 4 days for fungal growth which
was expressed as log10 CFU per organ, mean±SD.
Histological Analysis
Lungs were removed and immediately fixed in 10% neutral
buffered formalin (Bio-optica, Milan) for 24 h, embedded in
paraffin, sectioned into 3–4µm and stained with Periodic
Acid-Schiff reagent. Histology images were acquired using a
microscope (BX51 Olympus) with a 40× objective equipped with
a high-resolution DP71 camera (Olympus).
Isolation of Splenic Macrophages and
Conidiocidal Activity
Adherent spleen cells were isolated after treating the whole organ
with the injection of 2mL of Collagenase D (Sigma) at 2 mg/mL.
The spleen tissue was cut into small pieces and incubated for
20min at 37◦C in the enzyme solution. The cell suspension and
remaining tissue fragments were suspended in culture medium
and gently passed using a syringe plug through a 100µm cell
strainer to obtain a single cell suspension. Cells were cultured
in a 75 cm2 flasks and were allowed to adhere for 4 h at
37◦C and the non-adherent cells were removed after washing
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the monolayers with pre-warmed PBS. Five hundred thousand
adherent cells (macrophages) were then incubated at 37◦C with
resting Aspergillus conidia (fungi/cell ratio 1:3) for 120min
in 96-well flat-bottom microtiter plates and the percentage of
CFU inhibition (mean), referred to as conidiocidal activity, was
determined as follows: 100–(CFU in experimental group/CFU in
control cultures)× 100.
Human Bronchial Epithelial Cells and
Human PBMC Culture and Treatment
Human bronchial epithelial (HBE) cells were obtained from
lung transplants (CF patients homozygous for the CFTR 1F508
mutation) or lung resections (non-CF patients) and cultured
as described (24). PBMC fractions were obtained by density
centrifugation of diluted blood (one part blood to one part
pyrogen-free saline) over Ficoll-Paque (Pharmacia Biotech;
Uppsala). PBMCs were washed twice in saline and suspended in
culture medium supplemented with gentamicin 1%, L-glutamine
1%, and pyruvate 1%. The cells were counted in a Bürker
counting chamber, and their number was adjusted to 5 × 106
cells/ml. Five hundred thousand PBMCs in a volume of 200 µl
per well were incubated at 37◦C in round-bottom 96-well, in the
presence of 10% human pooled serum, with stimuli or culture
medium alone. Cells were treated for 24 h with either IFNγ (200
U/ml) or A. fumigatus conidia (1:20 cell/conidia ratio). In the
latter condition, amphotericin B was added after 6 h to prevent
hyphal formation.
Immunofluorescence Staining
Monocytes from healthy donors were exposed to live A.
fumigatus conidia. After washout, cells were fixed in 2%
formaldehyde for 40min at room temperature and permeabilized
in a blocking buffer containing 5% FBS, 3% BSA, and 0.5%
Triton X-100 in PBS. The cells were then incubated overnight
at 4◦C with primary antibody against IDO1 protein (IDO
antibody LS-C153780) in a buffer containing 3% BSA and
0.1% Triton X-100 in PBS. After extensive washing with PBS,
the cells were incubated at room temperature for 60min
with 1:400 secondary anti-mouse IgG–TRITC antibody (Sigma-
Aldrich). Alexa Fluor R© 488 phalloidin was used for selective
labeling of F-actin and nuclei were counterstained with DAPI.
Images were acquired using a fluorescence microscope (BX51,
Olympus) with a 100× objective and analySIS image processing
software (Olympus).
Western Blotting
Cells were lysed in 2x Laemmli buffer (Sigma-Aldrich). Blots
of cell lysates were incubated with an antibody against
IDO1 (clone 10.1, Millipore) followed by IgG–HRP-conjugated
secondary antibody (Sigma–Aldrich) after separation in 10 or
12% Tris/glycine SDS gel and transferred to a nitrocellulose
membrane. A cell lysate of IFNγ-stimulated HeLa cells was used
as positive control in selected experiments for correct assignment
of IDO1 band. Normalization was performed probing the
membrane with mouse-anti-β-tubulin antibody (Sigma–Aldrich,
clone T9026). Chemiluminescence detection was performed with
LiteAblotPlus chemiluminescence substrate (Euroclone S.p.A),
using the ChemiDocTM XRS+Imaging system (Bio-Rad), and
quantification was obtained by densitometry image analysis using
Image Lab 6.0 software (Bio-Rad).
Real-Time PCR
Real-time PCR was performed using the iCycler iQ detection
system (Bio-Rad) and iTaqTM Universal SYBR R© Green
Supermix (Biorad). Total RNA was extracted using RNeasy
Mini Kit (QIAGEN, Milan, Italy) and reverse transcribed
with Sensiscript Reverse Transcriptase (QIAGEN) according
to the manufacturer’s directions. Amplification efficiencies
were validated and normalized against β-actin. The thermal
profile for SYBR Green real-time PCR was at 95◦C for 3min,
followed by 40 cycles of denaturation for 30 s at 95◦C and an
annealing/extension step of 30 s at 60◦C. Each data point was
examined for integrity by analysis of the amplification plot. The
following primers were used: human IDO1: forward TCACAG
ACCACAAGTCACAG, reverse GCAAGACCTTACGGACAT
CT; human ACTB: forward CACTCTTCCAGCCTTCCTTCC,
reverse ACAGCACTGTGTTGGCGTAC; mouse Tnf : forward C
GAGTGACAAGCCTGTAGCC, reverse AAGAGAACCTGGG
AGTAGACAAG; mouse Actb: forward AGCCATGTACGTAG
CCATCC, reverse CTCTCAGCTGTGGTGGTGAA.
ELISA
Human IL-6, IL-8, and IL-17A cytokine concentration was
determined in HBE supernatants or in BAL from HSCT
patients by using specific ELISA kits according to manufacturers’
instructions (eBioscience Inc., R&D System and Biolegend).
Kynurenine and Tryptophan Assay
IDO functional activity was measured in vitro in terms of
the ability to metabolize tryptophan to kynurenine whose
concentrations were measured by high-performance liquid
chromatography (25).
Statistical Analysis
One-way ANOVA with Bonferroni post-hoc test was used to
determine the statistical significance. Significance was defined as
p < 0.05. Data are pooled results (mean ± SD) or representative
images from three experiments. GraphPad Prism software 6.01
(GraphPad Software) was used for analysis.
RESULTS
Genetic Variability at IDO1 Locus
Associates With Aspergillus Infection in
CF Patients
The eight tagSNPs encompassing IDO1/IDO2 loci have been
successfully genotyped in the CF cohort with genotyping rate
above 90%, not showing significant deviation from HWE
and having MAFs comparable to the ones reported for the
European population of the 1,000 Genomes Consortium (26)
(Supplementary Table 1). Linkage disequilibrium (LD) analysis
of the tagSNPs revealed the existence of two LD blocks of 11 and
7 kb, respectively, with the first one spanning from the 5′-end to
Frontiers in Immunology | www.frontiersin.org 5 May 2019 | Volume 10 | Article 890
Napolioni et al. IDOs Polymorphisms in Human Aspergillosis
FIGURE 1 | Linkage disequilibrium among selected IDO1/IDO2 tagSNPs in
the cohort of CF patients. Haplotype blocks are defined according to the solid
spine of LD algorithm. Linkage disequilibrium is expressed in r2.
the 4th intron of IDO1 locus, and the second one ranging from
the last intron of IDO1 to the first intron of IDO2 (Figure 1).
Haplotype analysis of the two LD blocks showed a
significant association of the first LD block with Aspergillus
infection (omnibus-P = 0.001), while the testing of the
second LD block did not turn significant (omnibus-P =
0.137). In particular, haplotype 3 (H3) and 4 (H4) at
the first LD block displayed significant association with
reduced (H3, OR = 0.278, P = 0.001) and increased
(H4, OR = 2.710, P = 0.008) risk of Aspergillus infection
(Table 3).
Single SNP analysis of the eight tagSNPs across the two loci
reported the nominal association of IDO1 rs3808606 (additive
OR = 1.513, P = 0.044; recessive OR = 2.283, P = 0.017),
IDO1 rs9657182 (recessive OR = 2.236, P = 0.024) and IDO2
rs7846217 (dominant OR= 1.989, P= 0.037) with increased risk
of Aspergillus infection (Table 4).
IDO1 rs3808606 and IDO2 rs7846217
Influence Immune Responses to A.
fumigatus in vitro
IDO1 rs3808606, located on the first LD block, showed the
most consistent association signal in the single-SNP analysis
and it is a whole-blood eQTL for IDO1 according to Haploreg
v4.1 (27). IDO2 rs7846217, despite being located in the first
intron of IDO2 and in the second LD block in our analysis,
is in LD with putative regulatory sites located toward the 3′-
end of IDO1 (Intron 9-Exon10-3′UTR) and a whole-blood eQTL
for IDO1 according to Haploreg v4.1 (27). Therefore, to gain
mechanistic insights for the association of genetic variability
at the IDO1 locus with Aspergillus infection, we performed
functional assays according to IDO1 rs3808606 and IDO2
rs7846217 SNPs.
We first evaluated the expression and function of IDO1
in HBE cells from CF patients according to their rs3808606
genotype. IDO1 mRNA levels were lower in T/T carriers as
compared to the C/C genotype (Figure 2A). The stimulation
with Aspergillus conidia or IFNγ induced IDO1 mRNA in HBE
cells carrying the C/C genotype, and in lower amount, in HBE
cells carrying the T/T genotype (Figure 2A). Quantification of
the kynurenine/tryptophan ratio demonstrated that resting HBE
cells bearing the T/T genotype produced levels of kynurenines
that were below the threshold of detection and remained low even
in the presence of Aspergillus conidia or IFNγ (Figure 2B). These
results demonstrate that HBE cells from CF patients bearing the
T/T genotype at rs3808606 display defective mRNA expression
and enzymatic activity of IDO1, both in resting conditions and
upon stimulation with conidia. Further confirming the impaired
IDO1 activity, the levels of IL-6 were higher in HBE cells bearing
the T/T genotype as compared to those bearing the C/C genotype
(Figure 2C).
Consistent with IDO2 rs7846217 being a whole-blood eQTL
for IDO1, HBE cells showed impaired IDO1 expression upon
stimulation with IFNγ when bearing the C/C, but not the T/T,
genotype (Figure 2D). Similarly, human monocytes stimulated
with Aspergillus conidia showed reduced expression of IDO1
when bearing the C/C, but not the T/T, genotype (Figure 2E).
Interestingly, the two non-synonymous IDO2 SNPs,
rs10109853 (NP_919270.2:p.Arg248Trp), and rs4503083
(NP_919270.2:p.Tyr359Ter), which profoundly impair IDO2
activity, were not associated with A. fumigatus infection in CF
patients (Table 4).
Overall, the genetic association study in the cohort of CF
patients would suggest, and confirm, the key role played by IDO1
in response to the fungus, as two distinct SNPs, located within
and downstream the IDO1 gene, that impair IDO1 function
along with an increased inflammatory response, are risk factors
for aspergillosis in these patients. At variance, IDO2 appears
dispensable as SNPs that profoundly affect its expression or
function do not associate with an increased risk.
IDO1 rs7820268 and IDO2 rs10109853 and
rs4503083 Associate With Aspergillus
Infection in HSCT Patients
Based on the results obtained in the CF cohort, we extended our
analyses of IDO1/IDO2 polymorphisms to the cohort of HSCT
patients. Five of the eight tagSNPs encompassing IDO1/IDO2
loci have been successfully genotyped in the HSCT cohort with
genotyping rate above 90% (Supplementary Table 1). The MAF
at the five tagSNPs is comparable to the ones reported for
the European population of the 1,000 Genomes Consortium
(26) (Supplementary Table 1). No significant differences inMAF
were detected between CF and HSCT patients, and no linkage
disequilibrium was detected among the 5 tagSNPs analyzed.
However, both IDO2 rs10109853 and rs4503083 showed
significant deviation from HWE (Supplementary Table 1). In
particular, the genotype distribution of rs4503083 deviates from
HWE only in recipients (P = 0.0007), suggesting a possible
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TABLE 3 | Haplotype association test in the cohort of CF patients.
LD block Haplotype rs9657182 rs3808606 rs7820268 Freq cases Freq controls OR P
1 1 C T C 49.7% 41.1% 1.410 0.089
2 T C T 34.1% 37.1% 0.859 0.487
3 C C C 5.5% 17.8% 0.278 0.001
4 T C C 9.8% 3.3% 2.710 0.008
LD block Haplotype rs3739319 rs16888361 rs7846217 Freq cases Freq controls OR P
2 1 G G T 34.5% 45.0% 0.640 0.041
2 A A T 24.1% 21.9% 1.190 0.460
3 A G T 20.7% 18.8% 0.970 0.906
4 G G C 18.4% 12.9% 1.550 0.112
5 G A T 2.2% 1.4% 3.120 0.164
LD blocks were defined using Haploview (19) according to the solid spine algorithm. Haplotype association tests were performed using PLINK (21), adjusting for age-at-sampling and
sex. Significant results are highlighted in bold.
TABLE 4 | Single-SNP association test in the cohort of CF patients.
SNP ALLELE N MODEL OR P MODEL OR P MODEL OR P
rs9657182 T 270 ADD 1.186 0.408 DOM 0.825 0.529 REC 2.236 0.024
rs3808606 T 264 ADD 1.513 0.045 DOM 1.388 0.310 REC 2.283 0.017
rs7820268 T 271 ADD 0.857 0.479 DOM 0.743 0.311 REC 1.032 0.944
rs3739319 A 267 ADD 1.108 0.612 DOM 0.955 0.882 REC 1.462 0.279
rs16888361 A 263 ADD 1.307 0.253 DOM 1.319 0.349 REC 1.744 0.324
rs7846217 C 251 ADD 1.590 0.093 DOM 1.989 0.037 REC 0.901 0.899
rs10109853 T 248 ADD 0.995 0.982 DOM 0.890 0.730 REC 1.137 0.731
rs4503083 A 250 ADD 1.060 0.798 DOM 0.997 0.992 REC 1.368 0.541
Genotype association tests were performed by logistic regression using PLINK (21), adjusting for age-at-sampling and sex. Nominally significant results are highlighted in bold. ADD,
Additive; DOM, Dominant; REC, Recessive.
predisposing effect to the underlying pathology. Conversely,
when separating recipients from donors according to rs10109853,
no significant deviation from HWE was detected. The analysis
of clinical/demographical characteristics in transplant recipients
showed that both HLA matching and underlying disease
status significantly affected the risk of Aspergillus infection
(Table 2). Thus, we considered these two variables as covariates
in the logistic regression models testing the association of
IDO1/IDO2 SNPs with Aspergillus infection. Genetic association
results are reported in Table 5. IDO1 rs7820268 showed a
significant association in transplant recipients, with minor allele
T increasing additively the risk of Aspergillus infection (RR =
1.685, P= 0.009). Moreover, the two IDO2 SNPs affecting protein
coding sequence, rs10109853 and rs4503083, double the risk of
A. fumigatus infection when present in the HSCT donors in a
genetic recessive model (rs10109853, RR = 2.214, P = 0.012;
rs4503083, RR= 2.841, P = 0.015, Table 5).
IDO1 rs7820268 SNP Influences
IDO1 Function
To investigate whether the IDO1 rs7820268 polymorphism
was associated with impaired enzyme expression and activity,
we first measured IDO1 protein levels in PBMC from healthy
controls and found a reduced expression in both resting and
IFNγ-stimulated PBMC bearing the T/T genotype (Figure 3A).
We also measured the kynurenine/tryptophan (Kyn/Trp) ratio in
the supernatants of PBMC left untreated or stimulated with IFNγ
and found decreased levels among carriers of T/T compared
with C/C genotypes, indicating a reduced enzymatic activity
(Figure 3B). These results are in agreement with published
data (28).
Consistent with the notion that inflammatory responses
are increased in conditions of impaired IDO1 function (9),
the levels of cytokines in the bronchoalveolar lavage (BAL)
fluids of patients with Aspergillus showed significant differences
according to IDO1 rs7820268 genotype, being Th17 (IL-8 and
IL-17A) higher in C/T+T/T carriers compared to C/C patients
(Figure 3C). Together, these results suggest that impaired IDO1
function along with increased inflammatory response are risk
factors for aspergillosis in HSCT patients similarly to what
observed in CF patients.
IDO2 in Hematopoietic Cells Protects
Against Aspergillosis in a Murine Model
of HSCT
The finding that the IDO2 SNPs displayed nominal associations
with A. fumigatus infection when present in the HSCT donors
prompted us to study the potential role of IDO2 in hematopoietic
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FIGURE 2 | IDO1 rs3808606 and IDO2 rs7846217 impair IDO1 induction in vitro. HBE cells from CF patients carrying the two homozygous variants at rs3808606
(C/C, light gray bars; T/T, dark gray bars) (A–C) or rs7846217 (T/T, major allele; C/C, minor allele) (D,E) were treated with A. fumigatus conidia (A–C,E) or IFNγ
(A,B,D). Cell lysates were evaluated for IDO1 mRNA expression by RT-PCR (A) or protein levels by Western blot (D). mRNA levels are expressed as relative levels of
unstimulated (none) HBE cells from the CF patient carrying the major allele. Protein values are expressed as relative levels of unstimulated (none) HBE cells from the
non-CF patient. Supernatants were analyzed for kynurenines and tryptophan levels by high-performance liquid chromatography (B) and for IL-6 levels by ELISA (C).
Monocytes from healthy donors carrying the two homozygous variants at rs7846217 (T/T, major allele; C/C, minor allele) were treated with A. fumigatus conidia (in the
inset) and evaluated by immunofluorescence for the expression of IDO1 (red). Phalloidin was used to stain actin filaments (green) (E). Shown is a representative
experiment from three independent experiments.
transplantation. To this purpose, we resorted to Balb/c mice
transplanted with bone marrow derived cells from Ido1−/−
or Ido2−/− (kindly donated by G.C. Prendergast (Lankenau
Institute for Medical Research (LIMR), USA) mice, before
challenge with A. fumigatus. Mice were assessed for fungal
burden in the lung, parameters of inflammatory pathology and
antifungal effector activity. We found an increased local fungal
burden in Ido1−/− or Ido2−/− reconstituted mice (Figure 4A)
that was associated with a more severe immunopathology,
particularly in Ido2−/−-reconstituted mice (Figure 4B), and an
increased Tnf expression (Figure 4C). Of interest, a significant
reduction of conidiocidal activity in splenic macrophages
was also observed in Ido2−/−-reconstituted mice (Figure 4D).
Collectively, these results suggest that IDO2 may play an
unanticipated role in A. fumigatus infection by sustaining the
phagocytic antifungal effector activity.
DISCUSSION
The results presented in this work extend our current knowledge
on the role of IDOs in the host response to Aspergillus. By
performing genetic association studies in CF patients and in
recipients of HSCT, we confirmed the pivotal role of IDO1 in
balancing immunity and tolerance to the fungus in the two
clinical settings. It is known that IDO1 is defective in CF patients
(8) and that it plays a role in aspergillosis in HSCT (9). Therefore,
it is not surprising that SNPs reducing the expression and
function of IDO1 are associated with aspergillosis in CF and
HSCT patients, although further studies are required to establish
how the single SNPs, alone or in combination, modulate IDO1
expression and function in the two cohorts of patients.
With regard to IDO2, our study showed that the two IDO2
SNPs, leading to truncated or catalytically impaired IDO2
protein, do not associate with an increased risk for aspergillosis in
CF patients. However, the same two IDO2 SNPs associated with
aspergillosis in HSCT recipients. Since IDO2 was cloned by three
independent groups (12–14), deciphering the function of IDO2
has remained enigmatic until the generation of IDO2 knock-out
mice (29), when evidence of specific roles has begun to emerge.
A substantial body of evidence has prompted the concept that
IDO2 might act as a pro-inflammatory mediator in autoimmune
diseases, specifically autoimmune arthritis (30–32), systemic
lupus erythematosus (33) and in contact hypersensitivity (29). In
these pathological settings, the role of IDO2 is B cell-intrinsic
and likely affects the cross-talk between B and T cells (33).
Interestingly, the clinical manifestation of aspergillosis in CF
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TABLE 5 | Genetic association testing in the BMT cohort.
Additive Dominant Recessive
SNP Allele N RR P RR P RR P
RECIPIENTS
rs7820268 T 293 1.685 0.009 2.350 0.016 1.535 0.360
rs16888361 A 300 1.416 0.140 1.590 0.150 1.462 0.460
rs7846217 C 303 0.921 0.790 0.845 0.650 1.176 0.820
rs10109853 T 293 1.109 0.620 1.342 0.430 0.982 0.960
rs4503083 A 304 1.004 0.990 0.979 0.950 1.095 0.890
DONORS
rs7820268 T 325 0.777 0.210 0.986 0.960 0.152 0.066
rs16888361 A 328 0.932 0.770 0.923 0.780 0.900 0.860
rs7846217 C 320 0.984 0.960 0.957 0.900 1.250 0.840
rs10109853 T 314 1.217 0.400 0.789 0.430 2.214 0.012
rs4503083 A 322 0.996 0.990 0.730 0.320 2.841 0.015
P-values and relative risk (RR) were calculated using competing risk logistic regression models, adjusting for HLA matching and underlying disease, considering transplant related
mortality and relapse as competing risks. Statistically significant results are marked in bold. Nominally-significant results are highlighted in Italics.
FIGURE 3 | IDO1 rs7820268 associates with defective IDO1 expression and enzymatic activity. (A,B) PBMC from donors carrying the two homozygous variants at
rs7820268 (C/C, light gray bars; T/T, dark gray bars) were treated with IFNγ. Cell lysates were evaluated for IDO1 protein expression by Western blot (A). Protein
values are expressed as relative levels of unstimulated (none) cells from donors carrying the major allele. Supernatants were analyzed for kynurenines and tryptophan
levels by high-performance liquid chromatography (B). Shown is a representative experiment from three independent experiments. (C) BAL from HSCT patients with
suspected infection carrying the homozygous or heterozygous variants at rs7820268 (C/C, light gray bars; C/T + T/T, dark gray bars) were evaluated for IL-8 and
IL-17A levels by ELISA (n = 7). Data are expressed as mean ± SD. *p < 0.05.
is in the form of allergic bronchopulmonary aspergillosis (3).
Although type I (IgE-mediated) hypersensitivity is common,
type III (IgG-mediated immune complex) and type IV (cell-
mediated) reactions have also been observed (34). Based on this
evidence, it is tempting to speculate that IDO2 might have a pro-
inflammatory role also in ABPA. On this regard, a preliminary
analysis testing the association between the eight tagSNPs with
IgE levels in CF patients yielded a significant association of
IDO2 rs16888361, with minor allele A carriers having higher IgE
levels compared to G/G carriers (β = 0.548, P = 0.005) (VN-
personal communication). The precise effect of rs16888361 on
IDO2 expression is currently under investigation. Interestingly,
a pro-inflammatory role of IDO2 has been recently suggested in
a study evaluating the influence of IDO2 gene status in tumor
progression and radiotherapy response in pancreatic ductal
adenocarcinoma (PDAC) (35). In particular, an IDO2 deficient
status, while being significantly absent in females with PDAC,
was associated with an improved immune signature, further
supporting the hypothesis that IDO2may promote inflammatory
responses, and this was associated with an improved survival in
response to adjuvant radiotherapy (35).
If overreacting immune responses occur in CF patients
in response to Aspergillus, HSCT patients are severely
immunocompromised and fail to properly counteract Aspergillus
infectivity. The kinetics and characteristics of the reconstitution
of the immune system after HSCT provides useful hints to
understand the susceptibility to infection (36). For instance,
while the absolute number of neutrophils was normalized after
30 days, ROS production was critically impaired in patients
with IA, and PMN-mediated killing of A. fumigatus remained
significantly reduced over 1 year in all HSCT recipients (36).
By using a murine model of HSCT, reconstitution of wild-type
mice with IDO2-deficient hematopoietic stem cells resulted in
a reduced conidiocidal activity of phagocytes, an event that
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FIGURE 4 | Mice transplanted with bone marrow-derived cells from Ido2−/− mice have a more severe pathology upon challenge with A. fumigatus. Balb/c mice were
transplanted with bone marrow derived cells from wild-type, Ido1−/− or Ido2−/− mice and challenged with A. fumigatus for 4 days. Mice were assessed for fungal
burden in the lung (log10 CFUs) (A), histology (PAS; the scale bar represents 500 or 100µm) (B), Tnf expression (RT-PCR) (C), and antifungal effector activity by
splenic macrophages (% killing) (D). Data represent pooled results (n = 3, mean ± SD) or representative images from three experiments. *p < 0.05; ns, not significant.
could favor Aspergillus dissemination. While IDO2 expression
and function have been consistently reported in B cells (29),
in DCs (37) and also in macrophages (29), to the best of our
knowledge it is unclear whether neutrophils express IDO2 and,
more importantly, how it correlates to their conidiocidal activity.
Studies are ongoing to address this issue.
Based on these observations, our results showing that IDO2
plays a context-dependent effect could be reconciled by taking
into account the different environment in which the cross-talk
between Aspergillus and the host takes place. Specifically, the
hypersensitivity response in the dysregulated immune system
in CF patients, in which IDO2 has a pro-inflammatory role,
and the inadequate phagocytic response in patients undergone
HSCT, in which IDO2 appears to be required for optimal
conidiocidal activity, might account for the distinct association
patterns of IDO2 SNPs with aspergillosis in the two cohorts
of patients.
Besides the specific role of IDO2, the interplay between
IDO1 and IDO2 is also an active field of investigation. While
the initial characterization of IDO2 was suggestive of a low
capacity to produce kynurenine, the recent optimization of
the requirements for proper evaluation of IDO2 enzymatic
activity has demonstrated a clear ability to catabolize Trp
(38). Therefore, IDO1 and IDO2 work in the same Trp-
catabolic pathway and competition for the same substrate might
occur. In addition, it has been suggested that IDO2 might
negatively regulate IDO1 by means of its heme-binding site
(39). Another possible interplay between IDO1 and IDO2,
besides the enzymatic activity, might be the regulation of their
reciprocal expression. For instance, it has been observed that
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both IDO1 and IDO2 are expressed in the epididymis and that
the expression of IDO2 is strongly upregulated in conditions
of IDO1 deficiency, although the increased expression was not
sufficient to compensate for the reduced levels of kynurenines
(40). A recent characterization of Ido1 knockout mice has
shown a defective IDO2 splicing and function, resulting in a
mosaic knock-out for IDO2, thus suggesting the existence of
an IDO1-IDO2 genetic interaction (29). Other studies have
reported a down-regulation of the Ido2 transcript in Ido1 knock-
out mice, which could be linked to loss of Ido2 regulatory
elements within the Ido1 gene (41). For instance, Ido2 mRNA
was decreased in naïve as well as diseased inguinal lymph
nodes from Ido1 knock-out mice in a model of collagen-induced
arthritis (42), and a 2-fold decrease was also reported in the
liver, but not spleen (30). How and whether IDO1 and IDO2
cross-regulate in the overall response to the fungus remain to
be investigated.
In conclusion, our results confirm and extend the role of
IDO1 in the response to Aspergillus, and identifies IDO2 as an
additional player. The development of selective IDO2 inhibitors,
such as tenatoprazole (43), chloroquine (44) or indoximod (45),
might help to differentiate between the distinct contributions
of IDO1 and IDO2 without the confounding effects of cross-
regulation at the genetic level. Alternative approaches may
include the use of SNP knock-in mice to recapitulate the
functional alterations observed in humans, a strategy already
employed in different contexts to mimic human phenotypes
(46–48). Whatever the approach, these results are expected
to pave the way for the pharmacological targeting of IDO2
in aspergillosis in high-risk patients, as recently explored in
autoimmune arthritis with the development of an IDO2-targeted
therapeutic antibody (32).
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